As Sun Pharma announces a Canadian launch for its licensed Winlevi clascoterone cream dermatology asset, the firm’s originating partner Cassiopea has struck further deals with Hikma and Glenmark for the acne treatment to be sold in Europe, the MENA region and South Africa.
Fresh deals with off-patent industry players Glenmark and Hikma have been seen for Cassiopea’s Winlevi (clascoterone) acne treatment, in Europe and South Africa and in the Middle East and North Africa region respectively, at the same time as existing North America licensee Sun Pharma announced a launch in Canada.
Sun has enjoyed rights to Winlevi for some time, entering into a partnership with Italy’s Cassiopea back in 2021 to...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
